Skip to content

STOCK REPORT · 237690 · KOSDAQ

ST Pharm

Star it to add it to your market report.

Price₩89,800-₩3,000 · -3.23%
A

Overall grade

70 pointsUpper band

Overall 70 points · Grade A, 15 points to Grade S

Metrics with values 8 of 9 · Top 27% among graded major stocksThe other metric is not measured in this update, because the data has no such item.

Financial summary

ST Pharm (237690) has an overall grade of A from financial statements, with a score of 70 out of 100. Category scores are Earnings 77 (Grade A), Financial health 80 (Grade A) and Dividends 44 (Grade C). Data as of Oct 23, 2026.

Reported figures: ROE 9.2%, Operating margin 16.56%, Revenue growth +21.16%, Debt-to-equity ratio 31.97%, Current ratio 226.2%, Dividend yield 0.33%, Payout ratio 18.3%, Dividend streak 5 yrs. Valuation: PER 34.36x, PBR 3.16x, Market cap ₩1.9T.

8 of the 9 graded metrics have values in this update.

The earnings metrics come from the 2025 annual report filed with the Financial Supervisory Service of Korea (DART). The share price was collected from the Korea Exchange on Oct 23, 2026. PER and PBR divide the market cap by the year-end figures. How the grades are calculated is set out in the grading methodology.

This summary restates reported financial figures. It does not forecast share prices or returns.

Valuation

PER34.36x
PBR3.16x
Market cap₩1.9T

52-week range

Now at 9% of range
₩82,100₩172,100
From high -47.8%From low +9.4%

Within their own 52-week ranges, 25% of major Korean stocks sit lower than this one.

About these metrics
PER
Price to earnings ratio (market cap ÷ annual net profit). A lower value means a lower price relative to profit.
PBR
Price to book ratio (market cap ÷ net assets). Below 1x, the market value is below book value.
Market cap
Share price × shares outstanding. The value the market puts on the whole company.
52-week high
The highest share price over the past year.
52-week low
The lowest share price over the past year.

All metric formulas and medians

Scores by category

Each metric out of 100 · category score is the average of three
A

Earnings

40% of overall · Upper band
77 pts
ROE9.2%
Metric score 61 out of 100
Operating margin16.56%
Metric score 81.4 out of 100
Revenue growth+21.16%
Metric score 91.2 out of 100

Each metric is scored out of 100, and the 77 above is the average of the three scores.

Metrics with values3 of 3

Fiscal year 2025 results

About these metrics
ROE
Return on equity. How much profit the company made on its own capital (equity).
Operating margin
Operating profit as a share of revenue: what the core business keeps.
Revenue growth
How much revenue changed compared with a year earlier.

All metric formulas and medians

A

Financial health

35% of overall · Upper band
80 pts
Debt-to-equity ratio31.97%
Metric score 98.7 out of 100
Current ratio226.2%
Metric score 92.6 out of 100
Interest coverageNot reported
Metric score 50 out of 100

Each metric is scored out of 100, and the 80 above is the average of the three scores.

Metrics with values2 of 3

Metrics shown as - in the table are not measured in this update, because the data has no such item.

About these metrics
Debt-to-equity ratio
Liabilities as a share of equity. A lower ratio means the company relies less on debt.
Current ratio
Assets that can turn into cash within a year, as a share of debts due within a year. At 100% or more they cover those debts.
Interest coverage
How many times operating profit covers interest expense. Below 1x, operating profit does not cover interest.

All metric formulas and medians

C

Dividends

25% of overall · Lower-middle band
44 pts
Dividend yield0.33%
Metric score 18.2 out of 100
Payout ratio18.3%
Metric score 58.2 out of 100
Dividend streak5 yrs
Metric score 56.7 out of 100

Each metric is scored out of 100, and the 44 above is the average of the three scores.

Metrics with values3 of 3

Fiscal year 2025 results

About these metrics
Dividend yield
Dividends paid over a year as a share of the current share price.
Payout ratio
The share of profit paid out as dividends. A very high ratio can be hard to keep up.
Dividend streak
How many years in a row the company has paid a dividend.

All metric formulas and medians

Metric scores are shown rounded to one decimal place, so a category score can differ by up to 1 point from a plain average of the three shown.

Strengths · Weaknesses

Strengths

  • Revenue is growing fast (+21.16% year on year)
  • Low debt burden (debt-to-equity ratio 31.97%)Below the median 54.9% of 64 Healthcare stocks
  • Ample short-term liquidity (current ratio 226.2%)
  • Has paid dividends for 5 yrs in a row

Weaknesses

No notable weaknesses among metrics with values

Only metrics that stand out as clearly good or weak against general benchmarks are listed. Where a comparison is possible, the position against the median of stocks in the same sector is shown too. The stock count on each sector line covers only stocks with that metric, so it differs by metric.

Metrics that moved the overall score

Baseline 50 + 20.6 = 70.6 pts
  • Debt-to-equity ratio+5.7 pts
  • Revenue growth+5.5 pts
  • Current ratio+5.0 pts
  • Operating margin+4.2 pts
  • ROE+1.5 pts
  • Payout ratio+0.7 pts
  • Dividend streak+0.6 pts
  • Interest coverage0.0 pts
  • Dividend yield-2.6 pts

Metric scores run up to 100, and the middle score is 50. If all nine metrics scored 50, the overall score would also be 50. Each bar is the contribution of one metric: how far its score sits from the 50 baseline, converted by that metric weight. Right means it raised the overall score, left means it lowered it.

Adding the nine contributions above to the baseline gives 70.6 points, and this stock's overall score is 70. The overall score is calculated from unrounded metric scores and then truncated, while the contributions here are rounded to one decimal place, so the two can differ by up to 1 point. Metrics that are not measured values still carry a contribution, because their scores did go into the overall score and hiding them would hide part of the basis of the grade.

Sector comparison

Healthcare · 71 stocks
MetricST PharmSector medianRank in sector
PER34.4x34.3x
PBR3.2x6.7x
ROE9.2%9.2%
Operating margin16.6%13.0%
Debt-to-equity ratio32.0%54.9%
Dividend yield0.3%0.7%

Grey values on the right are sector medians

Metric ranks in sector

Closer to 1st sits further left
  • PERRank 27 of 52, top 52%
  • PBRRank 21 of 65, top 32%
  • ROERank 31 of 63, top 49%
  • Operating marginRank 31 of 67, top 46%
  • Debt-to-equity ratioRank 18 of 64, top 28%
  • Dividend yieldRank 34 of 52, top 65%

On the rank strip, the left end is 1st. PER, PBR and debt-to-equity ratio are ranked from the lowest value, and ROE, operating margin and dividend yield from the highest.

Sector medians cover the 71 Healthcare stocks listed on Jupick. Typical levels differ by sector, so this is reference information for a simple comparison and not a basis for investment decisions.

About these metrics
PER
Price to earnings ratio (market cap ÷ annual net profit). A lower value means a lower price relative to profit.
PBR
Price to book ratio (market cap ÷ net assets). Below 1x, the market value is below book value.
ROE
Return on equity. How much profit the company made on its own capital (equity).
Operating margin
Operating profit as a share of revenue: what the core business keeps.
Debt-to-equity ratio
Liabilities as a share of equity. A lower ratio means the company relies less on debt.
Dividend yield
Dividends paid over a year as a share of the current share price.

All metric formulas and medians

Where this score sits

73% of the major stocks graded by Jupick score lower than this. Stocks in the same Grade A: 145.

  • S172.8%
  • AThis stock14524.2%
  • B28948.2%
  • C12621%
  • D233.8%

The Grade A band runs from 70 to 84 points, 15 points wide. This stock's 70 points sit exactly on the lower boundary, and 15 points remain to 85, where Grade S starts.

Within the Healthcare sector alone, it ranks No. 14 of 71 stocks with an overall score, and the median overall score of the sector is 60.

Unlike metric values, the overall score uses the same baseline for every market and currency, so Korean and US stocks share one sample. The grade boundaries of 85, 70, 50 and 30 points apply equally to every stock, so the counts above are how the sample actually splits at those boundaries. Because one point can decide a grade, two stocks with different grades can be closer in score than two stocks with the same grade. The shares and ranks here describe only the major stocks Jupick covers, not every listed stock.

Stocks with similar score profiles

StockEarningsFinancial healthDividends
ST Pharm (237690, this stock)778044
AGigaVis818343
BCelltrion766942
AHPSP728350
BConstellation Energy786842

ST Pharm (237690) has category scores of Earnings 77 · Financial health 80 · Dividends 44. These are the four major stocks graded in all three categories whose profiles come closest, and no category differs by more than 12 points.

The three scores are given by Jupick from public financial metrics, each out of 100. A similar profile means similar grading results only. It does not mean the share prices move alike.

Ratios as amounts

Base ₩10,000

Every ratio metric of this stock, restated on the same amount. If each line used a different base, the amounts could not be compared, so every line starts from ₩10,000.

For every ₩10,000 of revenue: operating profit ₩1,660.Operating margin 16.6%

  • For every ₩10,000 of equityyearly net profit ₩920ROE 9.2%
  • If last year's revenue was ₩10,000this year's revenue ₩12,120Revenue growth 21.2%
  • For every ₩10,000 of equitydebt owed ₩3,200Debt-to-equity ratio 32.0%
  • For every ₩10,000 of debt due within a yearassets turning into cash within a year ₩22,620Current ratio 226.2%
  • For every ₩10,000 worth of sharesdividends over the last year ₩30Dividend yield 0.3%
  • For every ₩10,000 of net profitdividends paid to shareholders ₩1,830Payout ratio 18.3%
  • For ₩10,000 of net profitmarket value ₩344,000PER 34.4x
  • For ₩10,000 of book equitymarket value ₩32,000PBR 3.2x

The ₩10,000 base is an assumption chosen for easy reading, not this company's actual revenue or equity. The values multiply the ratios shown as they are and round to the nearest won, so they can differ from the source by a few won. Metrics that make no sense as amounts are left out: values that are not measured, values that cannot be confirmed as measured, and loss-making cases where the base amount does not hold.

Metrics that decide the grade

Overall 70 · Grade A

The overall score recalculated with just one of the nine metrics set to the middle score of 50. Only one metric changes at a time, and the other eight stay as they are.

5 of the nine metrics would each take the overall score out of Grade A if only that metric were 50.

Overall score with only this metric at 50

  • Debt-to-equity ratioBgrade64.3 ptsFinancial health · metric 98.7 · contribution +5.7
  • Revenue growthBgrade64.5 ptsEarnings · metric 91.2 · contribution +5.5
  • Current ratioBgrade65 ptsFinancial health · metric 92.6 · contribution +5.0
  • Operating marginBgrade65.8 ptsEarnings · metric 81.4 · contribution +4.2
  • ROEBgrade68.5 ptsEarnings · metric 61 · contribution +1.5

The scores above add up this stock's metric scores again with one of them set to 50. They are not new grades, and this stock's grade stays at A. Metric scores and contributions are rounded to one decimal place, so a change within 1 point of a boundary is not reported as a grade change. Changing two or more metrics at once was not calculated.

Where the share price enters the grade

The grade above turns 9 metrics into scores and combines them. Counting how many of them use the share price shows whether the grade moves when the price moves.

0 of 9 graded metrics use the share price

The 9 graded metrics stay the same when the share price moves.

  • Earnings grade metrics (3)Does not use the share price0 of 3 metrics use the share price
  • Financial health grade metrics (3)Does not use the share price0 of 3 metrics use the share price
  • Dividends grade metrics (3)Does not use the share price0 of 3 metrics use the share price
  • PER and PBRCome from the share price but are not scoredNot graded

For Korean stocks, Dividend yield is taken as stated in the disclosure, so it is not recalculated when the share price changes. What changes the grade is the next financial filing, not the share price.

Stocks with a value for each metric

The grade above uses 9 metrics. Each line shows how many major stocks have a value for that metric, so you can tell whether a blank is specific to this stock or common to most stocks.

8 of the 9 graded metrics have values.

  • ROEHas a value567 of 600 stocks have a value
  • Operating marginHas a value562 of 600 stocks have a value
  • Revenue growthHas a value570 of 600 stocks have a value
  • Debt-to-equity ratioHas a value559 of 600 stocks have a value
  • Current ratioHas a value545 of 600 stocks have a value
  • Interest coverageNot reported278 of 600 stocks have a valueMore than half of stocks have no value
  • Dividend yieldHas a value519 of 600 stocks have a value
  • Payout ratioHas a value507 of 600 stocks have a value
  • Dividend streakHas a value595 of 600 stocks have a value

Blank metrics on this stock: 1. Many other stocks are blank on them too.

Position in the market distribution

Korean stocks

Where the value of ST Pharm sits when the Korean stocks on Jupick are lined up from the smallest value, ignoring sector. Left is smaller, right is larger, and the shaded part is the middle half.

The thin lower axis counts the position again within the same sector (Healthcare) only. 4 of the metrics with a lower axis sit in a different band from the whole market. On those lines, the bracket under the upper axis marks the middle half that the sector's stocks take on the market axis, and the short line inside is their middle.

  • PER34.4x
  • PBR3.2xOn the upper axis, the middle half of these 32 stocks sits between 62.9% and 94.1%, with the middle at 83.7%.
  • ROE9.2%
  • Operating margin16.6%On the upper axis, the middle half of these 30 stocks sits between 4.2% and 91.5%, with the middle at 43%.
  • Debt-to-equity ratio32.0%On the upper axis, the middle half of these 32 stocks sits between 16.8% and 39.9%, with the middle at 28.1%.
  • Dividend yield0.3%On the upper axis, the middle half of these 15 stocks sits between 11.4% and 32.4%, with the middle at 20.5%.

Won and dollar stocks have different metric levels, so they are counted in separate samples. This is only where a value sits in a line-up, not a sign of good or bad and not an investment judgement. Stocks without the metric, and loss-making stocks where PER or PBR does not hold, are left out of the sample. The remaining sample size is shown on each line. The sector axis is not drawn when the same-currency, same-sector sample has fewer than 8 stocks.

Korean and US yardsticks

Healthcare sector

Where one value of ST Pharm sits among Korean stocks in the same sector, and among US stocks. Only ratio metrics that compare across currencies are used.

4 of the 6 compared metrics sit in different bands on the two yardsticks.

  • ROE 9.2% Korean 32 stocks · upper middle · 62.5% have a smaller value US 31 stocks · lower middle · 38.7% have a smaller value Gap between yardsticks 23.8 pp
  • Operating margin 16.6% Korean 30 stocks · upper middle · 63.3% have a smaller value US 37 stocks · lower middle · 45.9% have a smaller value Gap between yardsticks 17.4 pp
  • Debt-to-equity ratio 32.0% Korean 32 stocks · lower middle · 34.4% have a smaller value US 32 stocks · lowest quarter · 18.8% have a smaller value Gap between yardsticks 15.6 pp
  • PER 34.4x Korean 17 stocks · upper middle · 58.8% have a smaller value US 35 stocks · lower middle · 45.7% have a smaller value Gap between yardsticks 13.1 pp

Only metrics with at least 8 stocks on both sides are compared.

Next

Closest overall scores in HealthcareDongKookPharmaceuticalCo. 70 · Hanmi Pharm. 69
My market reportStar it to add it to My market report.

Investment notice

For information only. Not investment advice. Grades and figures are reference material calculated from public information. They do not ask anyone to trade a security and make no promise of returns. You are solely responsible for your investment decisions and their results, and Jupick accepts no legal liability for them.